ORNBV Orion Oyj Class B

Orion Research Foundation grants EUR 1,112,000 for research in 2024

Orion Research Foundation grants EUR 1,112,000 for research in 2024

Orion Research Foundation grants EUR 1,112,000 for research in 2024

Press release 15 November, 2023 at 9.00 EET

Orion Research Foundation sr is distributing EUR 1,112,000 in research grants based on applications for 2024. Orion Reaserch Foundation awards grants of max EUR 50,000 for 17 researchers for postdoctoral research and max EUR 6,000 for 95 young researchers for doctoral dissertation work. One of the postdoctoral grants was distributed from Maritza and Reino Salonen’s Fund which is administered by Orion Research Foundation.

Orion Research Foundation sr is annually distributing its return on investment and donations from Orion Corporation as grants for young researchers for doctoral dissertation work and postdoctoral research. In the last few years the Research Foundation has been distributing annual grants based on applications for the total sum of MEUR 1 for research in medicine, veterinary medicine, pharmacy and related sciences, such as chemistry and physics.

Grants for 2024

Grants for postdoctoral research, 20,000 – 50,000 euros

He Liye, Postdoctoral researcher, Helsingin yliopisto, Identifying multi-omics biomarker panels for prediction of treatment responses of patients with chronic lymphocytic leukemia (CLL) using machine learning models, 30,000 €

Hossain Iftakher, Senior Post-doctoral Clinical Researcher, Neurocenter, Turku University Hospital, Turun yliopisto, Uudet verestä mitattavat biomerkkiaineet akuutin diffuusin aksonivaurion saaneiden ja pitkäaikaisista jälkioireista kärsivien potilaiden tunnistamisessa, 30,000 €

Ignatenko Olesia, Biological sciences, Helsingin yliopisto, Defining neuronal mechanisms that control circulating lipoprotein levels and liver lipid content, 30,000 €

Kaivola Karri Kasperi, LT, National Institutes of Health, Lewyn kappale -patologian kertymisen ja etenemisen säätelymekanismit, 50,000 €

Kivioja (née Karjalainen) Riikka Johanna, FT, Baselin Yliopistollinen sairaala, Basel, Sveitsi, Functional analysis of hematopoietic stem cells carrying CALR mutations in models of myeloproliferative neoplasms, 20,000 €

Kuitunen Ilari Matti Eemeli, Dosentti, LT, Itä-Suomen yliopisto Kuopion kampus, Näyttöön perustuvaa hoitoa lasten yleisiin infektiotauteihin, 30,000 €

Kuusanmäki Heikki Aleksi, PhD, Helsingin yliopisto, Targeting drug resistance in TP53-mutated acute myeloid leukemia, 35,000 €

Niemelä Tytti Maaria, FM, ELT, hevossairauksien erikoiseläinlääkäri, Helsingin yliopisto, Kliinisen hevos- ja pieneläinlääketieteen osasto, Changes in prevalence of extracellular vesicles and fatty acid profile of synovial fluid and clinical signs of osteoarthritis following intra-articular platelet-rich plasma treatment in horses: a controlled clinical trial, 35,000 €

Nikkola Jussi Mikael, Lääketieteen tohtori, Tampereen yliopisto, Randomized Clinical Trials Evaluating Urine DNA Testing as a Substitute for Cystoscopy in Urothelial Carcinoma Diagnostics and Surveillance, 40,000 €

Puris Elena, Provisor, Itä-Suomen yliopisto Kuopion kampus, A.I. Virtanen Institute for Molecular Sciences, Unravelling the effects of tau pathology on neurovascular transporter protein expression in Alzheimer's disease, 35,000 €

Räisänen Laura Karelia, Lääketieteen tohtori, Tampereen yliopisto, Evaluating the role of oral vancomycin in the treatment of the colitis associated with PSC- Ulcerative Colitis (PSC-UC) by correlating disease phenotype and treatment responses to changes in the gut microbiota composition, 50,000 €

San Martin Galindo Paola, Helsingin yliopisto, Uncovering mechanisms of new compounds for persistent infections - a novel approach for discovering bacterial ligands, 35,000 €

Taavitsainen Sinja Julia, Filosofian tohtori, Karoliininen instituutti, Sensitive detection of circulating tumor DNA fraction dynamics and evaluation of its clinical utility in metastatic castration-resistant prostate cancer, 40,000 €

van der Kolk Bertine Willemina (Birgitta), Researcher, Helsingin yliopisto, Obesity and aging: effects on adipose tissue mitochondria, inflammation, and insulin resistance in monozygotic twin pairs discordant for BMI, 30,000 €

Virtanen Jenni Maaret Elina, Filosofian maisteri, Helsingin yliopisto, Ortho- ja parapoxvirusten diagnostiikka, leviäminen ja monimuotoisuus, 30,000 €

Virtanen Jussi Eemil Iisakki, LT, korva-, nenä- ja kurkkutautien erikoislääkäri, Tampereen yliopisto, In vitro modeling of human respiratory and olfactory epithelium to understand olfactory pathophysiology, 40,000 €

Maritza and Reino Salonen’s fund

Björnholm Lassi, Lääketieteen tohtori, filosofian maisteri, Oulun yliopisto, Kliinisen lääketieteen tutkimusyksikkö, Prenatal maternal predictors of brain structural development, 30,000 €

Orion Reaserch Foundation awards grants of max EUR 50,000 for 17 researchers for postdoctoral research. These grants are in total EUR 590,000.

        

Grants for doctoral dissertation work, 3,000 – 6,000 euros

In addition, Orion Research Foundation has awarded EUR 3,000 – 6,000 for 95 researchers for doctoral dissertation work. These grants are in total EUR 522,000.

Orion Research Foundation sr

For further information:

Anu Imppola

Manager, Orion Research Foundation sr

Puh: +358 (0)10 426 3803

anu.imppola(at)orion.fi



Publisher

Orion Research Foundation sr

Attachment



EN
15/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion and Glykos announce the extension of their research collaboratio...

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs ORION CORPORATION PRESS RELEASE 17 JUNE 2025 at 9.00 EEST         Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates (ADCs). Under the extended agreement, Orion gain...

 PRESS RELEASE

Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan ...

Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien kehittämiseksi ORION OYJ        LEHDISTÖTIEDOTE        17.6.2025 KLO 9.00          Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien kehittämiseksi Orion Oyj ja Glykos Finland Oy laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien (antibody-drug conjugate, ADC) kehittämiseksi. Laajennettu sopimus antaa Orionille oikeuden hyödyntää Glykosin ADC-teknologioita kolm...

 PRESS RELEASE

U.S. FDA approves third indication of darolutamide for patients with a...

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST           U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor (ARi) for the treatment of patients with hormone-sensitive prostate cancer (mHSPC), in combination with androgen deprivation therapy (ADT), with or without chemotherapy.This third approval is based on positive results from the pivotal Phase III ...

 PRESS RELEASE

Yhdysvaltain lääkeviranomainen FDA hyväksyi kolmannen käyttöaiheen dar...

Yhdysvaltain lääkeviranomainen FDA hyväksyi kolmannen käyttöaiheen darolutamidille edennyttä eturauhassyöpää sairastavien potilaiden hoidossa ORION OYJLEHDISTÖTIEDOTE3.6.2025 klo 23.30          Yhdysvaltain lääkeviranomainen FDA hyväksyi kolmannen käyttöaiheen darolutamidille edennyttä eturauhassyöpää sairastavien potilaiden hoidossa Darolutamidi on ensimmäinen ja ainoa androgeenireseptorin estäjä, joka on Yhdysvalloissa saanut FDA:lta hyväksynnän levinneen hormonisensitiivisen eturauhassyövän (mHSPC) hoitoon yhdistettynä tavanomaiseen hormonaaliseen hoitoon (androgeenideprivaatioterapi...

 PRESS RELEASE

Orion announces agreement with Shilpa Medicare for Recombinant Human A...

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market ORION CORPORATION PRESS RELEASE 23 MAY 2025 at 12.40 EEST         Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited (“Shilpa”), have entered into an agreement to commercialise Recombinant Human Albumin in Europe. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications. Shilpa’s Recombinant Human Albumin is ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch